Dentate gyrus volume deficit in schizophrenia

Soichiro Nakahara, Soichiro Nakahara, Jessica A. Turner, Jessica A. Turner, Jessica A. Turner, Vince D. Calhoun, Vince D. Calhoun, Vince D. Calhoun, Vince D. Calhoun, Kelvin O. Lim, Bryon Mueller, Juan R. Bustillo, Daniel S. O'Leary, Sarah McEwen, James Voyvodic, Aysenil Belger, Daniel H. Mathalon, Daniel H. Mathalon, Judith M. Ford, Judith M. FordFabio MacCiardi, Mitsuyuki Matsumoto, Steven G. Potkin, Theo G.M. Van Erp, Theo G.M. Van Erp

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Schizophrenia is associated with robust hippocampal volume deficits but subregion volume deficits, their associations with cognition, and contributing genes remain to be determined.Methods Hippocampal formation (HF) subregion volumes were obtained using FreeSurfer 6.0 from individuals with schizophrenia (n = 176, mean age ± s.d. = 39.0 ± 11.5, 132 males) and healthy volunteers (n = 173, mean age ± s.d. = 37.6 ± 11.3, 123 males) with similar mean age, gender, handedness, and race distributions. Relationships between the HF subregion volume with the largest between group difference, neuropsychological performance, and single-nucleotide polymorphisms were assessed.Results This study found a significant group by region interaction on hippocampal subregion volumes. Compared to healthy volunteers, individuals with schizophrenia had significantly smaller dentate gyrus (DG) (Cohen's d = -0.57), Cornu Ammonis (CA) 4, molecular layer of the hippocampus, hippocampal tail, and CA 1 volumes, when statistically controlling for intracranial volume; DG (d = -0.43) and CA 4 volumes remained significantly smaller when statistically controlling for mean hippocampal volume. DG volume showed the largest between group difference and significant positive associations with visual memory and speed of processing in the overall sample. Genome-wide association analysis with DG volume as the quantitative phenotype identified rs56055643 (β = 10.8, p < 5 × 10-8, 95% CI 7.0-14.5) on chromosome 3 in high linkage disequilibrium with MOBP. Gene-based analyses identified associations between SLC25A38 and RPSA and DG volume.Conclusions This study suggests that DG dysfunction is fundamentally involved in schizophrenia pathophysiology, that it may contribute to cognitive abnormalities in schizophrenia, and that underlying biological mechanisms may involve contributions from MOBP, SLC25A38, and RPSA.

Original languageEnglish (US)
Pages (from-to)1267-1277
Number of pages11
JournalPsychological medicine
Volume50
Issue number8
DOIs
StatePublished - Jun 1 2020

Bibliographical note

Funding Information:
Financial support. This work was supported by the National Center for Research Resources at the National Institutes of Health [grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center)], the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR000153, and the National Institutes of Health through 5R01MH094524, P20GM103472, and R21MH097196. The funding sources had no role in the study design, conduct of the study, data collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Funding Information:
Conflict of interest. Dr Soichiro Nakahara’s effort was supported by Astellas Pharma Inc. while he was a visiting scholar in the University of California, Irvine. Dr Bustillo consulted with Novartis and Otsuka Pharmaceuticals. Dr Mathalon consulted for Boerhinger Ingelheim and Takeda. Dr Preda consulted for Boehringer-Ingelheim. Dr Potkin has financial interests in Bristol-Myers Squibb, Eisai, Inc., Eli Lilly, Forest Laboratories, Genentech, Janssen Pharmaceutical, Lundbeck, Merck, Novartis, Organon, Pfizer, Roche, Sunovion, Takeda Pharmaceutical, Vanda Pharmaceutical, Novartis, Lundbeck, Merck, Sunovion and has received grant funding from Amgen, Baxter, Bristol-Myers Squibb, Cephalon, Inc., Eli Lilly, Forest Laboratories, Genentech, Janssen Pharmaceutical, Merck, Otsuka, Pfizer, Roche, Sunovion, Takeda Pharmaceutical, Vanda Pharmaceutical, NIAAA, NIBIB, NIH/ NCRR, University of Southern California, UCSF, UCSD, Baylor College of Medicine. Dr Van Erp has had a contract with Otsuka Pharmaceuticals. The remaining authors declare no potential conflict of interest.

Keywords

  • genetics
  • genome-wide association analysis
  • hippocampus
  • imaging
  • subfield

Fingerprint Dive into the research topics of 'Dentate gyrus volume deficit in schizophrenia'. Together they form a unique fingerprint.

Cite this